Addition of silymarin to renin–angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial

Abstract

Silymarin did not show a significant reduction in the primary and secondary outcomes. Importantly, silymarin treatment was associated with a significant reduction in the hospitalization rate.

The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction

“…Our results on blood lipids (TC, TG, LDL-C, and HDL-C) were in line with the study of Mohammadi et al [19] who integrated 10 clinical trials. However, there were differences compared with the study of Hadi et al [16] who reported that silymarin supplementation did not significantly reduce FBG, TC, and TG using 7 trials and the study of Voroneanu et al [23] who used 5 RCTs to reveal silymarin supplementation had no effects on lipid profile (TC, TG, and HDL-C). These discrepancies may be resulted from an increased sample size in our study.…”

“…Finally, 16 studies fulfilled the eligibility criteria and were included for this meta-analysis. [ 12 13 14 15 22 23 24 25 26 27 28 29 30 31 32 33 ]…”

Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

“…In addition, combined therapy of Chinese herbal medicine and ACEI/ARB could exert a greater beneficial action on proteinuria, UAER, urinary albumin to creatinine ratio (UACR) and urinary protein to creatinine ratio than ACEI/ARB alone 19 . Besides the details demonstrated below, the results from those studies investigating the clinical efficacies of Chinese medicine on DN are also displayed in the Supporting Information Table S1 13 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 .…”

“…Some bioactive phytochemicals contained in Chinese medicines have been extracted and isolated using modern technologies, then developed as principal or adjuvant therapies and widely used for the purpose of treating DN. Modern pharmacological researches and clinical trials have demonstrated the therapeutic effects of these phytochemicals, mainly belonging to the classic of polyphenols (breviscapine, puerarin, resveratrol, safflower yellow, silymarin), alkaloids (berberine, ligustrazine, paeony glucosides, tripterygium glycosides) and hydroxyanthraquinones (emodin) that are discussed below in order 30 , 31 , 32 , 33 , 34 , 35 , 54 , 55 , 56 , 57 .…”

“…Silymarin is the main bioactive components extracted from Fructus Silybi ( Silybum marianum ), which approximately (70%–80%) consists of a mixture of three flavonolignans (silybin, silydianin, and silychristin). Recent studies have suggested that silymarin possesses functions of antioxidation, hepato-protection, and reno-protection 56 . A randomized placebo-controlled trial has assessed the reno-protective effect of silymarin against DN in 102 patients, but there were no significant differences in the primary and renal outcomes between the two groups treated with silymarin (150 mg per time, 3 times per day) and placebo after 2-year intervention, though with a significant reduction in the hospitalization rate 56 .…”